Ipca Laboratories Ltd's Q3FY25 Quarter Results
- 14 Feb 2025
Result Summary
- Ipca Laboratories Ltd reported a 4.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 9.2%.
- Its expenses for the quarter were down by 6.8% QoQ and up 2.3% YoY.
- The net profit increased 12.5% QoQ and increased 25.0% YoY.
- The earnings per share (EPS) of Ipca Laboratories Ltd stood at 9.8 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 2265.48 | 2381.16 | 2075.31 | -4.9% | 9.2% |
Total Expenses | 1897.56 | 2036.33 | 1854.43 | -6.8% | 2.3% |
Profit Before Tax | 367.92 | 344.83 | 288.89 | 6.7% | 27.4% |
Tax | 90.59 | 99.39 | 66.24 | -8.9% | 36.8% |
Profit After Tax | 276.36 | 245.75 | 221.00 | 12.5% | 25.0% |
Earnings Per Share | 9.80 | 9.10 | 7.10 | 7.7% | 38.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Ipca Laboratories Ltd is a well-established pharmaceutical company known for its expertise in manufacturing and marketing pharmaceutical formulations and active pharmaceutical ingredients (APIs). Operating primarily in the healthcare sector, the company is involved in the production of a wide range of therapeutic solutions, including anti-malarials, anti-bacterials, and anti-diabetics. Ipca Laboratories has a significant presence in both domestic and international markets, exporting its products to over 120 countries. While specific recent developments are not available in the provided data, the company is recognized for its commitment to quality and innovation in the pharmaceutical industry.
Revenue
In Q3FY25, Ipca Laboratories Ltd reported a total income of ₹2265.48 crores, which marks a decrease of 4.9% compared to the previous quarter (Q2FY25) where the income was ₹2381.16 crores. However, when compared to the same quarter in the previous year (Q3FY24), there was a 9.2% increase from ₹2075.31 crores. This year-over-year growth indicates a positive trend in revenue generation despite the quarter-over-quarter decline. The data shows that the company's revenue performance has maintained a generally upward trajectory over the past year.
Profitability
For Q3FY25, Ipca Laboratories Ltd recorded a profit before tax of ₹367.92 crores, which represents an increase of 6.7% from the ₹344.83 crores reported in Q2FY25. Year-over-year, the profit before tax grew by 27.4% from ₹288.89 crores in Q3FY24. The company's profit after tax for Q3FY25 was ₹276.36 crores, up 12.5% from the previous quarter and 25.0% higher than the same quarter last year. This growth in profitability is further reflected in the earnings per share, which rose to ₹9.80 in Q3FY25, a 7.7% increase from Q2FY25 and a 38.0% rise from Q3FY24. The data highlights a robust improvement in profitability metrics over the past year.
Operating Metrics
The total expenses for Ipca Laboratories Ltd in Q3FY25 were ₹1897.56 crores, a decrease of 6.8% compared to Q2FY25's expenses of ₹2036.33 crores. Compared to Q3FY24, there was a modest increase of 2.3% from ₹1854.43 crores. The tax expenses also saw a reduction of 8.9% quarter-over-quarter from ₹99.39 crores in Q2FY25 to ₹90.59 crores in Q3FY25, while year-over-year, the tax expenses increased by 36.8% from ₹66.24 crores in Q3FY24. These operational metrics indicate changes in the cost structure and tax obligations of the company within the analyzed periods.
